环磷腺苷葡胺治疗急性心肌梗死的临床观察

发布时间：2019-02-11 21:06

【摘要】：目的:探讨环磷腺苷葡胺治疗急性心肌梗死的临床疗效及安全性。方法:选择2015年5月-2016年1月我院收治的急性心肌梗死患者80例,按随机数字表法分为对照组和观察组,各40例。对照组患者予以常规治疗;观察组患者在对照组的基础上加用环磷腺苷葡胺注射液120 mg加入5%葡萄糖注射液250 m L中,ivgtt,qd。两组患者均治疗7 d。观察两组患者临床疗效及治疗前后血清超敏C反应蛋白(hs-CRP)、N末端脑利钠肽前体(NT-pro BNP)水平,并记录两组患者不良反应发生情况。结果:观察组患者临床总有效率(92.50%)显著高于对照组(75.00%),差异有统计学意义(P0.05)。治疗前,两组患者血清hs-CRP、NT-pro BNP水平比较,差异无统计学意义(P0.05);治疗后,两组患者血清hs-CRP、NT-pro BNP水平均显著降低,且观察组水平显著低于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:环磷腺苷葡胺治疗急性心肌梗死疗效显著,能明显降低患者血清hs-CRP和NT-pro BNP水平,且安全性较高。
[Abstract]:Objective: to investigate the clinical efficacy and safety of meglumine cyclophosphate in the treatment of acute myocardial infarction. Methods: 80 patients with acute myocardial infarction from May 2015 to January 2016 were randomly divided into control group (n = 40) and observation group (n = 40). The patients in the control group were treated with routine therapy, and the patients in the observation group were treated with adenosine cyclophosphate injection (120 mg) and 5% glucose injection (250ml) on the basis of the control group, and ivgtt,qd. was added to the control group. Both groups were treated for 7 days. The clinical efficacy and serum levels of hs-CRP), N terminal brain natriuretic peptide precursor (NT-pro BNP) were observed before and after treatment, and the adverse reactions of the two groups were recorded. Results: the total effective rate of the observation group (92.50%) was significantly higher than that of the control group (75.00%), the difference was statistically significant (P0.05). Before treatment, there was no significant difference in serum hs-CRP,NT-pro BNP levels between the two groups (P0.05). After treatment, the serum hs-CRP,NT-pro BNP levels of the two groups were significantly decreased, and the level of observation group was significantly lower than that of the control group, the difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: meglumine cyclophosphate is effective in the treatment of acute myocardial infarction and can significantly reduce the levels of hs-CRP and NT-pro BNP in serum of patients with acute myocardial infarction.
【作者单位】：齐齐哈尔医学院附属第一医院西药局;齐齐哈尔医学院附属第一医院心血管内科;
【分类号】：R542.22

【相似文献】